iRhythm Technologies’ Zio ambulatory cardiac monitors have the potential to change how doctors screen for atrial fibrillation and other arrythmias by combining miniaturized biosensors and data analytics into a wearable device, CEO Quentin Blackford explains to Bloomberg Intelligence. In this Vanguards of Health Care podcast episode, Blackford sits down with BI analyst Matthew Henriksson for an in-depth interview to talk about iRhythm and how its systems allow patients to be monitored outside of medical offices without disrupting their everyday lives.

Athenahealth's Strategic Reset, Push for Speed in Ambulatory Care
51:10

Inside Insilico Medicine’s AI Strategy and Lilly Breakthrough
59:53

Abridge Moving AI From Scribing to Clinical Workflows
51:43